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Applicability to Clinical PracticeDiscussion
 Pathophysiology of Major Depressive Disorder
➢ Monoamine-deficiency hypothesis only partly explains the pathogenesis of MDD.
➢ Other hypotheses in the pathophysiology of MDD include inflammatory cytokines, hypothalamus-pituitary-adrenal axis, glutamate receptors, BDNF dysfunction, increased apoptosis, & 
vitamin D dysregulation.
➢ Rot et al. (2009) found that a polymorphism of BDNF affects the intracellular transport and secretion of BDNF and may increase depression vulnerability.
➢ There is a multitude of interconnected systems involved in the pathophysiology of MDD.
 Cognitive & Emotional Biomarkers
➢ Castellano et al. (2016) found that both SSRIs and SNRIs reduced the affective symptoms in MDD, as well as significantly improved the global cognitive function. Both SSRIs and SNRIs 
improved executive function and verbal memory, however, this improvement was independent from the efficacy of affective symptoms. 
➢ Etkin et al. (2015) showed that remission rates with escitalopram treatment were higher for individuals predicted to remit with escitalopram than for those predicted to not remit and 
remission rates were higher if they received escitalopram versus sertraline or venlafaxine. Participants that were predicted to reach remission had slightly lower depressive severity, were 
more educated, and received a lower dose of escitalopram at week 8. The patients that were predicted not to reach remission had generally impaired cognitive functioning. Those predicted to 
not remit with escitalopram remitted at a lower rate if they received escitalopram compared with venlafaxine and sertraline. 
➢ Gyruk et al. (2016) found that that remitters to treatment were distinguished from nonremitters by greater pretreatment right dorsolateral prefrontal cortex (DLPFC) activation. “MDD 
patients who remitted were distinguished by relatively normal levels of DLPFC activation pretreatment, which attenuated posttreatment” (Gyruk, 2016, p.279). Patients who did not reach 
remission showed DLPFC hypoactivation at both pretreatment and posttreatment. A “failure to engage the DLPFC region may be a general marker of nonresponsiveness to treatment” 
(p.279), as stated by Gyruk et al. A region in the right inferior parietal cortex predicts HRSD remission differentially by SSRIs compared to SNRIs. Regarding effects of medications, Gyruk 
et al. found that “remitters specifically to SSRIs showed correspondingly normal levels of inferior parietal activation, which also attenuated posttreatment, while nonremitters to SSRIs 
showed parietal hypoactivation. Thus, SSRI and SNRI responders showed opposing patterns of activation in the parietal cortex”. 
Statement of the Problem
References
Major depressive disorder (MDD) is a neuropsychiatric condition that is becoming 
increasingly prevalent in our country. According to Cai, Huang, and Hao (2015), MDD is “common 
and devastating” (p. 61) and has a very complex pathophysiology. Until recently, a definitive 
etiology had not been found, however, new evidence has suggested that Brain-derived neurotrophic 
factor (BDNF) and cognitive-emotional biomarkers may be a key into the mechanism of this 
disorder.  
A literature review of articles found in PubMed, CINAHL, Cochrane Library, and 
PsychINFO within the last ten years focused on the hypotheses of the pathophysiology of MDD, 
cognitive-emotional biomarkers, and BDNF. The review found that MDD has a multitude of 
interconnecting systems that highlight its mechanism, and this is why it is so difficult to find a 
treatment option that works. However, cognitive-emotional biomarkers were able to predict the 
efficacy of certain antidepressants in the treatment of MDD. BDNF was also found to be decreased 
in patients with MDD and increased after treatment with certain medications. These systems may 
help predict better treatment response and an overall improvement of the burden of this disease.
Key Terms: brain-derived neurotrophic factor, sertraline, venlafaxine, venlafaxine 
hydrochloride, depressive disorder, serotonin and noradrenaline reuptake inhibitors, and serotonin 
uptake inhibitors
 In adults with MDD, does BDNF play a role in the pathophysiology of MDD?
 In treatment of adults with MDD, do cognitive biomarkers predict the efficacy and 
outcome of treatment and remission?
 In treatment of adults with MDD, does BDNF predict the efficacy and outcome of 
treatment and remission?
 According to Cai et al. (2015), “MDD can reduce the capacity of a patient to study, work, and 
engage in social skills” (p.61). It can also increase the risk of suicide and disability rate and has 
a very high recurrence rate. 
 According to the World Health Organization, there were 300 million patients with MDD in 
2015. “It is estimated that by 2020, the disease burden caused by MDD will be ranked next to 
ischemic heart disease, becoming the second most common cause of disability and death” (Cai, 
2015, p.61). 
 The etiology of MDD has not been completely understood, according to Ristevska-Dimitrovska 
et al. (2013), and many new hypotheses in the pathophysiology of MDD have been formulated. 
 Antidepressant treatment only has an efficacy of 60-65%, a remission rate of only 30%, and a 
high percentage of patients that do not show any improvement. Also, antidepressants increase 
the levels of these monoamine neurotransmitters in the central nervous system (CNS), but it 
often takes at least two weeks for them to take effect.
 Not having a definitive mechanism by which this disease works makes it harder to find 
treatment options that are going to provide the efficacy and tolerability that these patients need. 
As more definitive mechanisms are discovered, treatment options can be more effective as they 
are tailored to the specific mechanism.
 MDD, according to Cai et al. (2015), “is a mental disorder characterized by prominent and 
persistent low mood, mental retardation, cognitive impairment, volitional decline, and 
somatic symptoms” (p.61). 
 The Centers for Disease Control and Prevention (2016) states that almost 10% of adults 
aged 40-59, and more than 1 out of 20 Americans 12 years of age and older reported current 
depression. 
 “Cognitive deficits are considered as key symptoms of clinical depression that are 
associated both with suboptimal response to antidepressants and reduced remission rates” 
(Castellano, 2016, p.1295). 
 In the last decade, there has been an abundance of research showing that levels of 
neurotrophins, such as BDNF in the brain, may be involved in the pathophysiology of MDD 
and may accurately predict the efficacy of antidepressant medications and the remission of 
depression. 
 The purpose of this review is to determine how BDNF and cognitive-emotional biomarkers 
factor into the pathophysiology of MDD, and if they can accurately predict the efficacy and 
outcome of certain antidepressants.
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 In clinical practice, MDD is a disease process that will be encountered many times in a 
provider’s career.
 Based on cognitive and emotional tests performed before antidepressant treatment, 
studies were able to predict treatment response to certain SSRI’s and SNRI’s.
 BDNF is decreased in patients with MDD and certain antidepressants are able to 
increase this level. Some studies showed that a higher BDNF level showed a larger 
antidepressant response.
 If providers are able to predict whether certain medications will work before starting 
them, this can alleviate a large amount of stress and frustration.
➢ Cognitive and emotional tests performed prior to antidepressant treatment may be 
an option to predicting if a medication will work. 
➢ Also, measuring BDNF levels before and during the course of treatment may help 
providers predict if antidepressant treatment will work much sooner than has 
previously been possible.
 Both Cai et al. (2015) and Rot et al. (2009) stated that the pathophysiology of MDD has 
been mainly based on the monoamine-deficiency hypothesis. This hypothesis focuses on 
decreased levels of serotonin, norepinephrine, and dopamine being the cause of MDD. 
However, there are antidepressant medications to acutely increase all of these 
neurotransmitters in the brain, and there is only a small number of patients that actually 
reach remission. This suggests that there is more to the pathogenesis of depression.
 Begni et al. (2016) stated that neurotrophins, such as BDNF, regulate growth and 
apoptosis of neurons in the CNS and PNS. If BDNF levels are decreased, an impairment 
of brain development and brain plasticity will occur. 
 Yang et al. (2016) stated that neurogenesis and neuroplasticity are mechanisms involved 
in memory and learning, and if disrupted as with decreased BDNF levels, MDD may 
occur. 
 Etkin et al. (2015) found that “response with antidepressant medication can be reliably 
predicted for outpatients with MDD by their pretreatment performance on a 
standardized test battery of cognitive and emotional function”.
 Gyruk et al. (2016) showed that activation in the frontoparietal region of the brain 
predicted remission with antidepressant treatment, particularly SSRIs.
 Overall, the review of literature showed that BDNF levels were decreased in patients 
with MDD. It also showed that these BDNF levels increase over time with 
antidepressant treatment with certain medications. These results may offer a tremendous 
gain in the treatment of adults with MDD and may finally be able to help find treatment 
options for patients that will work. 
➢ Ristevska-Dimitrovska et al. (2009) found that antidepressant treatment increased serum BDNF levels in depressed patients that were close to the healthy controls. In the integrated 
study, lower levels of BDNF were shown while depressive symptoms were evident. 
➢ Cattaneo et al. (2010) found that the BDNF serum and mRNA leukocyte levels showed a significant decrease in the MD patients compared to controls, as well as increased the level 
past baseline with escitalopram treatment. The drug treatment improved symptoms and significantly decreased MADRS scores.
➢ Ghosh et al. (2015) found that plasma BDNF levels increased in MDD patients after 12-week treatment with both desvenlafaxine and fluoxetine. 
➢ Kurita et al. (2012) found that in the remission group, the MADRS scores reduced significantly over the course of treatment and the BDNF levels increased significantly with clinical 
improvement. Patients in the non-responder group did not show much difference in the MADRS scores, however, the plasma BDNF levels were still significantly decreased during 
the syndrome’s 8-12-week period.
 Brain Derived Neurotrophic Factor
➢ Begni et al. (2016) proposed that BDNF is a very complex neurotrophin.
➢ Ide et al. (2015) stated that “BDNF is highly expressed in the cortex, hippocampus, limbic 
structures, cerebellum, and the olfactory bulb” (p.120). 
➢ When BDNF is secreted, it binds to certain receptors & initiates a series of downstream 
signaling cascades which leads to prevention of cell death & neuronal differentiation. 
 BDNF as a Target for Treatment Intervention
➢ Wolkowitz et al. (2011)  found that serum BDNF levels were significantly lower in patients 
with MDD vs. healthy controls. This study also found that BDNF levels increased over the 
course of antidepressant treatment and that subjects with initially higher serum BDNF levels 
showed a larger antidepressant response to sertraline and escitalopram after 8 weeks of 
treatment. 
➢ Matrisciano et al. (2009) showed that BDNF levels were lower in depressed patients versus 
healthy controls. A significant increase in BDNF serum levels after 5 weeks of treatment 
with sertraline and after 6 months of sertraline and venlafaxine were present. All three 
antidepressants were effective in relieving depression symptoms after 5 weeks and 6 months, 
despite their different effects on serum BDNF levels. 
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